300601 康泰生物
已收盘 01-06 15:00:00
资讯
新帖
简况
康泰生物2025年第四季度“康泰转2”转股42张，总股本微增至约11.17亿股
中金财经 · 01-05 19:33
康泰生物2025年第四季度“康泰转2”转股42张，总股本微增至约11.17亿股
股市必读：12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元
证券之星 · 01-05 02:58
股市必读：12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元
每周股票复盘：机构净卖出康泰生物（300601）733.45万元
证券之星 · 01-03
每周股票复盘：机构净卖出康泰生物（300601）733.45万元
12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元
证券之星 · 2025-12-31
12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元
康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验
智通财经 · 2025-12-24
康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验
康泰生物：2025年上半年研发投入3.34亿元
证券之星 · 2025-12-18
康泰生物：2025年上半年研发投入3.34亿元
康泰生物（300601）披露重组乙肝疫苗获临床试验批准，12月17日股价上涨1.15%
证券之星 · 2025-12-17
康泰生物（300601）披露重组乙肝疫苗获临床试验批准，12月17日股价上涨1.15%
康泰生物(300601.SZ)：重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目取得临床试验批准
智通财经 · 2025-12-17
康泰生物(300601.SZ)：重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目取得临床试验批准
康泰生物：成人疫苗布局及国际化战略进展
证券之星 · 2025-12-17
康泰生物：成人疫苗布局及国际化战略进展
康泰生物：公司销售费用率维持在行业平均水平
证券之星 · 2025-12-17
康泰生物：公司销售费用率维持在行业平均水平
12月16日康泰生物创60日新低，嘉实中证疫苗与生物技术ETF基金重仓该股
证券之星 · 2025-12-16
12月16日康泰生物创60日新低，嘉实中证疫苗与生物技术ETF基金重仓该股
12月4日康泰生物现1笔大宗交易 机构净买入708.81万元
证券之星 · 2025-12-04
12月4日康泰生物现1笔大宗交易 机构净买入708.81万元
康泰生物（300601）股东杜伟民质押305万股，占总股本0.27%
证券之星 · 2025-11-25
康泰生物（300601）股东杜伟民质押305万股，占总股本0.27%
康泰生物最新公告：控股股东一致行动人杜兴连拟减持不超过0.24%公司股份
证券之星 · 2025-11-10
康泰生物最新公告：控股股东一致行动人杜兴连拟减持不超过0.24%公司股份
康泰生物最新公告：四价流感病毒裂解疫苗（6-35月龄人群）开启Ⅰ期临床试验
证券之星 · 2025-11-03
康泰生物最新公告：四价流感病毒裂解疫苗（6-35月龄人群）开启Ⅰ期临床试验
股市必读：康泰生物三季报 - 第三季度单季净利润同比下降93.74%
证券之星 · 2025-10-28
股市必读：康泰生物三季报 - 第三季度单季净利润同比下降93.74%
康泰生物最新公告：前三季度营业收入20.63亿元同比增长2.24%
证券之星 · 2025-10-27
康泰生物最新公告：前三季度营业收入20.63亿元同比增长2.24%
康泰生物（300601）披露关于签署《许可终止协议》的公告，9月30日股价上涨1.63%
证券之星 · 2025-09-30
康泰生物（300601）披露关于签署《许可终止协议》的公告，9月30日股价上涨1.63%
康泰生物(300601.SZ)与阿斯利康签署许可终止协议
智通财经 · 2025-09-30
康泰生物(300601.SZ)与阿斯利康签署许可终止协议
康泰生物：三价流感病毒裂解疫苗上市许可申请获受理 将进一步丰富公司产品布局
中国财富通 · 2025-09-25
康泰生物：三价流感病毒裂解疫苗上市许可申请获受理 将进一步丰富公司产品布局
加载更多
公司概况
公司名称：
深圳康泰生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2017-02-07
主营业务：
深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是13价肺炎球菌多糖结合疫苗、无细胞百白破b型流感嗜血杆菌联合疫苗（四联苗）、冻干人用狂犬病疫苗（人二倍体细胞）、23价肺炎球菌多糖疫苗、重组乙型肝炎疫苗(酿酒酵母)、b型流感嗜血杆菌结合疫苗、吸附无细胞百白破联合疫苗、水痘减毒活疫苗。
发行价格：
3.29
{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":15.39,"timestamp":1767683019000,"preClose":15.34,"halted":0,"volume":10802567,"delay":0,"changeRate":0.0033,"floatShares":900000000,"shares":1117000000,"eps":-0.0898,"marketStatus":"已收盘","change":0.05,"latestTime":"01-06 15:00:00","open":15.4,"high":15.45,"low":15.22,"amount":166000000,"amplitude":0.015,"askPrice":15.39,"askSize":539,"bidPrice":15.38,"bidSize":604,"shortable":0,"etf":0,"ttmEps":-0.0898,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767749400000},"marketStatusCode":5,"adr":0,"adjPreClose":15.34,"symbolType":"stock","openAndCloseTimeList":[[1767663000000,1767670200000],[1767675600000,1767682800000]],"highLimit":16.87,"lowLimit":13.81,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116929375,"isCdr":false,"pbRate":1.78,"roa":"--","roe":"0.51%","epsLYR":0.18,"committee":-0.199593,"marketValue":17190000000,"turnoverRate":0.012,"status":0,"floatMarketCap":13857000000},"requestUrl":"/m/hq/s/300601","defaultTab":"news","newsList":[{"id":"2601885858","title":"康泰生物2025年第四季度“康泰转2”转股42张，总股本微增至约11.17亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885858","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601885858?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:33","pubTimestamp":1767612795,"startTime":"0","endTime":"0","summary":"中访网数据 深圳康泰生物制品股份有限公司于2026年1月5日发布公告，披露了其可转换公司债券“康泰转2”在2025年第四季度的转股情况。报告期内，共有42张“康泰转2”转换为公司股票，对应转股金额为4,200元，合计转为264股“康泰生物”A股股票。转股完成后，公司总股本由约11.17亿股微增至约11.17亿股。截至2025年12月31日，“康泰转2”剩余数量为19,989,910张，剩余票面总金额约为19.99亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260105/31915962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0201","300601","BK0239","BK0046"],"gpt_icon":0},{"id":"2601029089","title":"股市必读：12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601029089","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601029089?lang=zh_cn&edition=full","pubTime":"2026-01-05 02:58","pubTimestamp":1767553090,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，康泰生物报收于14.77元，下跌0.61%，换手率0.73%，成交量6.59万手，成交额9754.82万元。当日关注点来自交易信息汇总：12月31日主力资金净流出1207.98万元，占总成交额12.38%。大宗交易12月31日康泰生物现1笔大宗交易，机构净卖出733.45万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500000922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0239","BK0201"],"gpt_icon":0},{"id":"2600067641","title":"每周股票复盘：机构净卖出康泰生物（300601）733.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067641","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067641?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:44","pubTimestamp":1767379451,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，康泰生物报收于14.77元，较上周的15.12元下跌2.31%。本周，康泰生物12月29日盘中最高价报15.28元。12月31日盘中最低价报14.74元。康泰生物当前最新总市值164.97亿元，在生物制品板块市值排名17/51，在两市A股市值排名1191/5181。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"gpt_icon":0},{"id":"2595720346","title":"12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595720346","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595720346?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:33","pubTimestamp":1767173636,"startTime":"0","endTime":"0","summary":"证券之星消息，12月31日康泰生物发生大宗交易，交易数据如下：大宗交易成交价格14.77元，成交49.66万股，成交金额733.45万元，买方营业部为广发证券股份有限公司广州临江大道证券营业部，卖方营业部为机构专用。近三个月该股共发生2笔大宗交易，合计成交9536.0手。截至2025年12月31日收盘，康泰生物报收于14.77元，下跌0.61%，换手率0.73%，成交量6.59万手，成交额9754.82万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100031446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0046","BK0201"],"gpt_icon":0},{"id":"2593478445","title":"康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2593478445","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593478445?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:57","pubTimestamp":1766566638,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物 发布公告，公司全资子公司北京民海生物科技有限公司研发的吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗已完成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。本次五联疫苗开启Ⅲ期临床试验并成功完成首例受试者入组，表明该产品研发取得了阶段性进展，公司将积极推动该产品的临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300601","BK0046","BK0201","159646"],"gpt_icon":0},{"id":"2592290549","title":"康泰生物：2025年上半年研发投入3.34亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592290549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592290549?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:48","pubTimestamp":1766062131,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物12月17日在投资者关系平台上答复投资者关心的问题。康泰生物回复：您好，公司始终将研发创新作为驱动公司可持续发展的核心战略，长期保持高强度、持续性的研发投入，以技术壁垒构筑企业核心竞争力，2025年上半年公司研发投入为3.34亿元，占当期营业收入的23.96%，相较于2024年上半年同比增加了41.52%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800035253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300601","BK0201","BK0239"],"gpt_icon":0},{"id":"2592915818","title":"康泰生物（300601）披露重组乙肝疫苗获临床试验批准，12月17日股价上涨1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915818","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592915818?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:12","pubTimestamp":1765980744,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，康泰生物报收于15.0元，较前一交易日上涨1.15%，最新总市值为167.54亿元。公司近日发布公告称，其研发的重组乙型肝炎疫苗新增适用人群项目，获得国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意在16-64岁慢性乙肝临床治愈人群中开展预防HBsAg复阳的临床试验。该疫苗拟用于降低慢性乙肝临床治愈后HBsAg复阳风险，目前全球尚无同类产品获批用于该人群。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700039349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0239","BK0201"],"gpt_icon":0},{"id":"2592969169","title":"康泰生物(300601.SZ)：重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目取得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592969169","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592969169?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:09","pubTimestamp":1765966180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司研发的重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目于今日获得国家药品监督管理局出具的《药物临床试验批准通知书》，本品符合药品注册的有关要求，批准本品在慢性乙型肝炎功能性(临床)治愈人群中开展预防HBsAg复阳的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康泰生物(300601.SZ)：重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目取得临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300601","BK0046","159646","BK0201"],"gpt_icon":0},{"id":"2592299699","title":"康泰生物：成人疫苗布局及国际化战略进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2592299699","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592299699?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:09","pubTimestamp":1765966150,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物12月17日在投资者关系平台上答复投资者关心的问题。公司持续推进国际化战略，通过产品认证、注册申报及市场准入等多重举措拓展海外业务版图。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700029045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0046","BK0239","BK0201","300601"],"gpt_icon":0},{"id":"2592899691","title":"康泰生物：公司销售费用率维持在行业平均水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2592899691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592899691?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:06","pubTimestamp":1765965966,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物12月17日在投资者关系平台上答复投资者关心的问题。康泰生物回复：您好，公司目前销售费用率维持在行业平均水平，目前公司自身销售团队及服务团队合计已有千余人，团队多年来累计了丰富的销售经验，现已覆盖全国31个省、自治区、直辖市。公司主要客户是疾病预防控制中心，疾病预防控制中心为事业单位，具有良好的信誉及履约能力，应收账款回收的风险较小。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700028894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300601","BK0201"],"gpt_icon":0},{"id":"2591860135","title":"12月16日康泰生物创60日新低，嘉实中证疫苗与生物技术ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591860135","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591860135?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:41","pubTimestamp":1765870883,"startTime":"0","endTime":"0","summary":"证券之星消息，12月16日康泰生物创60日新低，收盘报14.83元，当日跌1.46%，换手率0.85%，成交量7.61万手，成交额1.13亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为嘉实基金的嘉实中证疫苗与生物技术ETF。嘉实中证疫苗与生物技术ETF目前规模为2.45亿元，最新净值0.6889，较上一交易日下跌1.2%，近一年上涨13.79%。该公募基金现任基金经理为周泉希。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600020275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","BK0239","159646","300601"],"gpt_icon":0},{"id":"2588002902","title":"12月4日康泰生物现1笔大宗交易 机构净买入708.81万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588002902","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588002902?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:58","pubTimestamp":1764838714,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日康泰生物发生大宗交易，交易数据如下：大宗交易成交价格15.51元，成交45.7万股，成交金额708.81万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交4570.0手。截至2025年12月4日收盘，康泰生物报收于15.51元，下跌0.51%，换手率0.77%，成交量6.91万手，成交额1.07亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400025521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0201","BK0046"],"gpt_icon":0},{"id":"2586245994","title":"康泰生物（300601）股东杜伟民质押305万股，占总股本0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586245994","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586245994?lang=zh_cn&edition=full","pubTime":"2025-11-25 18:41","pubTimestamp":1764067284,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物11月25日公开信息显示，股东杜伟民向招商证券股份有限公司合计质押305.0万股，占总股本0.27%。质押详情见下表：截止本公告日，股东杜伟民已累计质押股份4458.0万股，占其持股总数的15.65%。康泰生物主营业务：人用疫苗的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500029191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0046","BK0201"],"gpt_icon":0},{"id":"2582878847","title":"康泰生物最新公告：控股股东一致行动人杜兴连拟减持不超过0.24%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2582878847","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582878847?lang=zh_cn&edition=full","pubTime":"2025-11-10 19:29","pubTimestamp":1762774189,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司控股股东、实际控制人的一致行动人杜兴连计划自本公告披露之日起十五个交易日后的三个月内，以集中竞价或大宗交易方式减持公司股份不超过2,724,048股，即不超过公司总股本的0.24%。减持原因为个人资金需求，减持股份来源为公司首次公开发行前的股份（含因公司实施权益分派而相应增加的股份）。本次减持计划实施不会影响公司的治理结构和持续经营，不会导致公司控制权发生变化。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000028884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","300601","BK0239"],"gpt_icon":0},{"id":"2580229998","title":"康泰生物最新公告：四价流感病毒裂解疫苗（6-35月龄人群）开启Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2580229998","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580229998?lang=zh_cn&edition=full","pubTime":"2025-11-03 18:41","pubTimestamp":1762166475,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司研发的四价流感病毒裂解疫苗（6-35月龄人群）已完成Ⅰ期临床试验准备工作，开启Ⅰ期临床试验，并于近日成功完成首例受试者入组。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300028668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","BK0046","300601","BK0201"],"gpt_icon":0},{"id":"2578624262","title":"股市必读：康泰生物三季报 - 第三季度单季净利润同比下降93.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578624262","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578624262?lang=zh_cn&edition=full","pubTime":"2025-10-28 02:08","pubTimestamp":1761588496,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告康泰生物2025年三季报显示，主营收入20.63亿元，同比上升2.24%；归母净利润4915.77万元，同比下降86.0%；扣非净利润2787.89万元，同比下降90.82%。2025年第三季度单季度主营收入6.71亿元，同比下降17.74%；单季度归母净利润1162.49万元，同比下降93.74%；单季度扣非净利润942.03万元，同比下降94.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800001853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"gpt_icon":0},{"id":"2578157656","title":"康泰生物最新公告：前三季度营业收入20.63亿元同比增长2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578157656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578157656?lang=zh_cn&edition=full","pubTime":"2025-10-27 16:59","pubTimestamp":1761555598,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司第三季度营业收入6.71亿元，同比下降17.74%；归母净利润1162.49万元，同比下降93.74%。前三季度营业收入20.63亿元，同比增长2.24%；净利润4915.77万元，同比下降86%。报告期内，公司持续推进国际化战略，通过产品认证、注册申报及市场准入等多重举措拓展海外业务版图。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700022324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"gpt_icon":0},{"id":"2571326402","title":"康泰生物（300601）披露关于签署《许可终止协议》的公告，9月30日股价上涨1.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571326402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571326402?lang=zh_cn&edition=full","pubTime":"2025-09-30 22:16","pubTimestamp":1759241781,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，深圳康泰生物制品股份有限公司与阿斯利康UK Limited于2020年8月20日签署《许可协议》，阿斯利康独家授权公司在内地对ChAdOx1腺病毒载体新冠疫苗进行研发、生产及商业化。2021年9月3日双方签署《许可协议第一修正案》。鉴于新冠疫苗流行株及市场环境发生较大变化，双方经协商近日签署《许可终止协议》，原《许可协议》项下所有权利义务自终止协议生效之日起终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000040106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0201","300601"],"gpt_icon":0},{"id":"2571314599","title":"康泰生物(300601.SZ)与阿斯利康签署许可终止协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2571314599","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571314599?lang=zh_cn&edition=full","pubTime":"2025-09-30 16:09","pubTimestamp":1759219787,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 康泰生物 发布公告，2020年8月20日，公司与AstraZeneca UK Limited签署了《许可协议》，阿斯利康独家授权公司在中华人民共和国内对ChAdOx1腺病毒载体新冠疫苗进行研发、生产及商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU0889565916.HKD","BK0046","BK4585","LU2462157665.USD","300601","BK4568","BK0239","AZN","LU1829250122.USD","BK4588","BK0201","LU0109394709.USD","LU2236285917.USD","LU2417539215.USD","LU0320765992.SGD","LU2456880835.USD"],"gpt_icon":0},{"id":"2570009291","title":"康泰生物：三价流感病毒裂解疫苗上市许可申请获受理 将进一步丰富公司产品布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2570009291","media":"中国财富通","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570009291?lang=zh_cn&edition=full","pubTime":"2025-09-25 20:00","pubTimestamp":1758801614,"startTime":"0","endTime":"0","summary":"9月25日，康泰生物(300601.SZ)公告称，公司研发的三价流感病毒裂解疫苗上市许可申请近日获得国家药品监督管理局出具的《受理通知书》。该疫苗适用于3周岁及以上人群，用于预防疫苗相关型别的流感病毒引起的流行性感冒。目前国内已上市的流感病毒裂解疫苗厂家包括长春生物制品研究所有限责任公司、华兰生物疫苗股份有限公司等。若该产品顺利获批上市，将进一步丰富公司产品布局，增强公司的核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=VD5qDUfk4XE%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300601","BK0239","159646","BK0201","BK0046"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767730970033,"stockEarnings":[{"period":"1week","weight":0.0357},{"period":"1month","weight":-0.016},{"period":"3month","weight":-0.0834},{"period":"6month","weight":-0.0757},{"period":"1year","weight":-0.0441},{"period":"ytd","weight":0.042}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.1635},{"period":"1year","weight":0.2734},{"period":"ytd","weight":0.0289}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"63422人(较上一季度增加3.15%)","perCapita":"14196股","listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦","registeredCapital":"111692万元","survey":" 深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是13价肺炎球菌多糖结合疫苗、无细胞百白破b型流感嗜血杆菌联合疫苗（四联苗）、冻干人用狂犬病疫苗（人二倍体细胞）、23价肺炎球菌多糖疫苗、重组乙型肝炎疫苗(酿酒酵母)、b型流感嗜血杆菌结合疫苗、吸附无细胞百白破联合疫苗、水痘减毒活疫苗。","listedPrice":3.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}